

Supplementary Table S1. Current HPV infection and presence of female genital dysplasia

| | N=62 |
|--|-----------|
| HPV+ PCR, n (%) | 31 (50) |
| Genotype identification, n (%) | 56 (90.3) |
| HPV-HR, n (%) | 14 (25.0) |
| Number of HPV-HR serotypes, median (IQR) | 0 (0-0.5) |
| HPV-LR, n (%) | 17 (30.4) |
| Number of HPV-LR serotypes, median (IQR) | 0 (0-1) |
| LR- and HR-HPV coinfection, n (%) | 7 (12.5) |
| HPV 6, n (%) | 2 (3.6) |
| HPV 16, n (%) | 4 (7.1) |
| HPV 31, n (%) | 1 (1.8) |
| HPV 35, n (%) | 2 (3.6) |
| HPV 39, n (%) | 1 (1.8) |
| HPV 40, n (%) | 1 (1.8) |
| HPV 42, n (%) | 4 (7.1) |
| HPV 43, n (%) | 2 (3.6) |
| HPV 44, n (%) | 4 (7.1) |
| HPV 44/55, n (%) | 3 (5.4) |
| HPV 51, n (%) | 5 (8.9) |
| HPV 54, n (%) | 1 (1.8) |
| HPV 59, n (%) | 3 (5.4) |
| HPV 61, n (%) | 1 (1.8) |
| HPV 62, n (%) | 1 (1.8) |
| HPV 62/81, n (%) | 5 (8.9) |
| HPV 68, n (%) | 2 (3.6) |
| HPV 72, n (%) | 1 (1.8) |
| HPV 73, n (%) | 2 (3.6) |
| HPV 82, n (%) | 1 (1.8) |
| Simultaneous oral and genital HPV, n (%) | 3 (5.2) |
| Cervical Cytology, n (%) | |
| -Normal | 55 (88.7) |

| | |
|----------------------------------|---------|
| -LSIL | 3 (1.0) |
| -ASCUS | 4 (1.3) |
| Gynecological examination, n (%) | 1 (1.7) |
| -CIN 1 | 1 (100) |

IQR, interquartile range; PCR, polymerase chain reaction; HPV, human papillomavirus; LSIL, low-grade intraepithelial lesion; HSIL, high-grade intraepithelial lesion; ASCUS, atypical squamous cells of uncertain significance; CIN, cervical intraepithelial neoplasm.

Supplementary Table S2. Current HPV infection and the presence of anal dysplasia

| | N=288 |
|------------------------------------|-------------|
| HPV+ PCR, n (%) | 238 (82.6) |
| Identification of genotypes, n (%) | 281 (97.5%) |
| HPV-HR, n (%) | 189 (67.3) |
| Number of HPV-HR, median (IQR) | 1(0-2) |
| HPV-LR, n (%) | 168 (59.8) |
| Number of HPV-LR, median (IQR) | 1 (0-2) |
| HR- and LR-HPV coinfection, n (%) | 123 (43.8) |
| HPV 6 | 33 (11.7) |
| HPV 11 | 16 (5.7) |
| HPV 16 | 42 (14.9) |
| HPV 18 | 21 (7.5) |
| HPV 26 | 1 (0.4) |
| HPV 31 | 36 (12.8) |
| HPV 32 | 1 (0.4) |
| HPV 33 | 22 (7.8) |
| HPV 35 | 26 (9.3) |
| HPV 39 | 29 (10.3) |
| HPV 40 | 12 (4.3) |
| HPV 42 | 28 (10.0) |
| HPV 43 | 16 (5.7) |
| HPV 44 | 1 (0.4) |
| HPV 44/55 | 54 (19.2) |
| HPV 45 | 22 (7.8) |

| | |
|--|------------|
| HPV 51 | 23 (8.2) |
| HPV 52 | 33 (11.7) |
| HPV 53 | 12 (4.3) |
| HPV 54 | 12 (4.3) |
| HPV 56 | 24 (8.5) |
| HPV 58 | 23 (8.2) |
| HPV 59 | 33 (11.7) |
| HPV 61 | 24 (8.5) |
| HPV 62/81 | 54 (19.2) |
| HPV 66 | 18 (6.4) |
| HPV 67 | 13 (4.6) |
| HPV 68 | 41 (14.6) |
| HPV 69 | 4 (1.4) |
| HPV 70 | 27 (9.6) |
| HPV 71 | 2 (0.7) |
| HPV 72 | 24 (8.5) |
| HPV 73 | 21 (7.5) |
| HPV 82 | 12 (4.3) |
| HPV 84 | 12 (4.3) |
| Simultaneous oral and anal HPV infection | 25 (8.9) |
| | N =300 |
| Anal Cytology, n (%) | |
| -Normal | 118 (39.6) |
| -LSIL | 110 (36.9) |
| -HSIL | 8 (2.7) |
| -ASCUS | 33 (11.1) |
| -Not valid | 29 (9.7) |
| HRA, n (%) | 89 (30.9) |
| - LSIL (AIN 1) | 84 (29.2) |
| -HSIL (AIN 2-3 or carcinoma in situ) | 5 (1.7) |

IQR, interquartile range; PCR, polymerase chain reaction; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; ASCUS, atypical squamous cells of uncertain significance; HRA: high resolution anoscopy; AIN, anal intraepithelial neoplasm.